EBSAM
GILD icon

Eubel Brady & Suttman Asset Management’s Gilead Sciences GILD Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-250
Closed -$16K – 173
2021
Q2 		$16K Buy
+250
New +$16.7K ﹤0.01% 485

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's GILD Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Gilead Sciences (GILD) in Q3 2021, closing a stake of 250 shares — an estimated $16K sold.

Eubel Brady & Suttman Asset Management first reported a position in GILD in Q2 2021 and held it in 1 quarter. The position peaked at $16K in Q2 2021. 1,563 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Gilead Sciences position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 250 Gilead Sciences shares in Q3 2021, an estimated $16K.
  • Eubel Brady & Suttman Asset Management first reported a position in Gilead Sciences in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Gilead Sciences position peaked at $16K in Q2 2021.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.